Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study by George, J et al.
Association between cardiovascular events and
sodium-containing effervescent, dispersible, and
soluble drugs: nested case-control study
OPEN ACCESS
Jacob George senior lecturer/honorary consultant in clinical pharmacology 1, Waseem Majeed core
medical trainee in medicine 2, Isla S Mackenzie senior lecturer/honorary consultant in clinical
pharmacology 3, Thomas M MacDonald professor of clinical pharmacology 3, Li Wei senior lecturer
in medical statistics 3 4
1Division of Medical Science, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 2NHS Tayside, Ninewells Hospital, Dundee DD1 9SY,
UK; 3Medicines Monitoring Unit and Hypertension Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 4Department
of Practice and Policy, UCL School of Pharmacy, London WC1H 9JP, UK
Abstract
Objective To determine whether patients taking formulations of drugs
that contain sodium have a higher incidence of cardiovascular events
compared with patients on non-sodium formulations of the same drugs.
Design Nested case-control study.
Setting UK Primary Care Patients registered on the Clinical Practice
Research Datalink (CPRD).
Participants All patients aged 18 or over who were prescribed at least
two prescriptions of sodium-containing formulations or matched standard
formulations of the same drug between January 1987 and December
2010.
Main outcome measures Composite primary outcome of incident
non-fatal myocardial infarction, incident non-fatal stroke, or vascular
death. We performed 1:1 incidence density sampling matched controls
using the UK Clinical Practice Research Datalink (CPRD). For the
secondary analyses, cases were patients with the individual components
of the primary study composite endpoint of hypertension, incident heart
failure, and all cause mortality.
Results 1 292 337 patients were included in the study cohort. Mean
follow-up time was 7.23 years. A total of 61 072 patients with an incident
cardiovascular event were matched with controls. For the primary
endpoint of incident non-fatal myocardial infarction, incident non-fatal
stroke, or vascular death the adjusted odds ratio for exposure to
sodium-containing drugs was 1.16 (95% confidence interval 1.12 to
1.21). The adjusted odds ratios for the secondary endpoints were 1.22
(1.16 to 1.29) for incident non-fatal stroke, 1.28 (1.23 to 1.33) for all
cause mortality, 7.18 (6.74 to 7.65) for hypertension, 0.98 (0.93 to 1.04)
for heart failure, 0.94 (0.88 to 1.00) for incident non-fatal myocardial
infarction, and 0.70 (0.31 to 1.59) for vascular death. The median time
from date of first prescription (that is, date of entry into cohort) to first
event was 3.92 years.
Conclusions Exposure to sodium-containing formulations of
effervescent, dispersible, and soluble medicines was associated with
significantly increased odds of adverse cardiovascular events compared
with standard formulations of those same drugs. Sodium-containing
formulations should be prescribed with caution only if the perceived
benefits outweigh these risks.
Introduction
Excess dietary sodium is a major public health problem
worldwide. In response to a 2010 report by the Institute of
Medicine,1 the National Salt Reduction Initiative (NSRI) was
established with a goal to reduce dietary sodium consumption
in the United States by 20% in five years. Reducing sodium
intake in the US to the recommended 2.3 g/day (100 mmol/L
or one teaspoonful) could prevent 11 million cases of
hypertension, save $18bn (£11bn, €13bn) healthcare dollars,
and gain 312 000 quality adjusted life years (QALYs) valued
at $32bn annually.2 In the United Kingdom, the Food Standards
Agency also launched a campaign in 20023 to reduce salt intake
in the estimated 26 million people in the UK who have high
dietary sodium intake. It has been estimated that a 3 g/day
reduction in salt (1.2 g/day reduction in sodium) could prevent
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30 000 cardiovascular events and save the National Health
Service (NHS) at least £40m/year (€48m, $64m).4
Excess sodium in healthy individuals impairs endothelial
function, left ventricular relaxation, and cardiac repolarisation.5
Some of these effects could be independent of blood pressure
in patients with hypertension.6 While considerable efforts are
being made to reduce salt intake in the population in general
we were concerned that a high sodium load can be ingested
through certain formulations of medicines such as effervescent,
dispersible, and soluble formulations. As an example, the
recommended sodium intake for an adult in the UK is 2.4 g/day
(104 mmol/day). The dispersible and effervescent formulations
of paracetamol 500 mg, however, can contain 18.6 mmol and
16.9 mmol of sodium in each tablet, respectively, and therefore
the maximum daily dose of eight tablets/day results in the
ingestion of 148.8 mmol and 135.2 mmol of sodium,
respectively. This exceeds the recommended total daily
allowance of sodium for one drug alone. Added to a typical
Western diet, these drugs could result in high sodium intake.
Curiously, unlike foods, pharmaceutical manufacturers are not
placed under any restrictions or obligations with regards to
sodium content or labelling of these sodium-containing
formulations.
We hypothesised that sodium-containing formulations might
increase adverse cardiovascular outcomes. We compared the
risk of cardiovascular events in patients prescribed
sodium-containing formulations with the risk in those prescribed
standard tablet or capsular forms of the same drugs using the
Antithrombotic Trialists’ Collaboration (ATC) serious vascular
event composite endpoint of non-fatal myocardial infarction,
non-fatal stroke, or vascular death.7
Methods
Study design
This was a population based nested case-control study that used
the UK Clinical Practice Research Datalink (CPRD) database.
This is a large computerised database of anonymised
longitudinal medical records derived from primary care. It
contains data from over 500 primary care practices with 4.4
million active patients throughout the UK. The data have been
collected since 1987 and cover about 7% of the UK population.
The data from CPRD are validated and have been found to be
generalisable to the whole UK population.8
Study population
The study population consisted of residents in the UKwho were
registered with their general practitioner and had more than one
recorded contact from January 1987 to December 2010. Only
general practices that met standards predefined by CPRD,
registered as “up to standard” practices, were included in the
study.
Study patients
The study population comprised all patients aged 18 or over
who received at least two prescriptions of sodium-containing
formulations or matched standard formulations of the same drug
from January 1987 to December 2010. Within the category of
sodium-containing formulations, we selected only drugs with
more than 1000 prescriptions in the entire CPRD database.
Study cohort
Patients entered the study at the date of their first prescription
for sodium or standard drug during the study period and were
followed up until the end of December 2010. Patients were
censored if they experienced an outcome event, died, or left
their general practice during the study period or switched drugs.
Patients were excluded from the study if they had a malignancy
diagnosed (except basal cell carcinoma), malabsorption
syndromes, salt wasting conditions, or a recorded history of
alcohol/drug/substance abuse before the entry date. The above
procedure was repeated for each individual outcome.
Definition of cases and controls
All patients with incident cardiovascular events during follow-up
were identified by Read codes from the study cohort.
Cardiovascular events were defined by the first occurrence of
the Antithrombotic Trialists’ Collaboration serious vascular
event endpoint of non-fatal myocardial infarction, non-fatal
stroke, or vascular death.7 For each case, wematched one control
with incidence density sampling on year of birth, sex, and
general practice attended. The date of the first cardiovascular
event during the follow-up was defined as the index date for
each case and was used for the index date for the matched
controls. The above case and control selection procedure was
repeated for the individual components of the ATC event
endpoint: hypertension, incident heart failure, and all cause
mortality.
Drug treatments
We identified 24 different drugs with sodium-containing
formulations (dispersible, effervescent, and soluble) and a
further 116 different comparable standard formulations that
were non-dispersible, non-effervescent, or non-soluble versions
of the 24 sodium-containing drugs. Table 1 shows examples of
sodium-containing formulations⇓. The sodium content for each
sodium-containing formulation was obtained from the summary
of product characteristics or by contacting the individual
manufacturers when this information was not found in the
summary.
Covariates
The covariates included age, sex, body mass index (BMI),
smoking status, hypertension, peripheral vascular disease,
angina, chronic obstructive pulmonary disease (COPD), diabetes
mellitus, chronic kidney disease, migraine, heart failure,
oesophageal disease (which might make the prescription of
soluble/effervescent drugs more likely), and prescriptions of
potassium sparing diuretics (because of potassium’s potential
beneficial vasoactive effects9).For co-prescribed drugs,
covariates adjusted for in the model included angiotensin
converting enzyme inhibitors or angiotensin receptor blockers,
proton pump inhibitors, oral steroids, non-steroidal
anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors,
antipsychotic drugs, anti-HIV therapy, statins, and antiplatelets.
Statistical analysis
Data are presented as mean (SD) for continuous variables and
as numbers (%) for categorical variables.We performed χ2 tests
and analysis of variance to determine significant differences.
Conditional logistic regression analysis was used to determine
odds ratios for the association between patients prescribed
sodium-containing formulations and the risk of cardiovascular
outcomes as well as all cause mortality. We also carried out
univariate and multivariate analyses. In the multivariate models
we adjusted the odd ratios for all covariates between the study
groups. Appendix 1 shows a stepwise analysis for the primary
outcome and a correlation matrix for the factors analyses. Data
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were missing for 14% for smoking and 28% for BMI. The
multiple imputation analysis included all variables used in the
final analysis with 10 imputations by using the Markov chain
Monte Carlo method to produce imputed data. We carried out
sensitivity analyses to deal with the missing data mechanisms.
A complete case analysis was conducted (see appendix 2 for
details). All results were expressed as odds ratios (95%
confidence intervals). All statistical analyses were carried out
with SAS (version 9.2).
Results
Patients’ characteristics
We included 1 292 337 patients in the study. The mean
follow-up time was 7.23 years. During follow-up 61 072 events
that met the definition of the primary cardiovascular endpoint
occurred. The median time from date of first prescription (that
is, date of entry into cohort) to first occurrence of non-fatal
myocardial infarction, non-fatal stroke, or vascular death was
3.92 years. Table 2⇓ shows the baseline characteristics between
the groups. The cohort of cases had significantly more (all
P<0.01) smokers, history of angina, heart failure, chronic
obstructive pulmonary disease, peripheral vascular disease,
diabetes mellitus, and chronic kidney disease. Likewise there
were also more prescriptions for drugs for cardiovascular
disease, NSAIDs, and potassium supplements than in the control
group. All these parameters, however, were included in and
adjusted for in the final analysis.
Primary endpoint
The 61 072 cases were matched with the same number of
controls in the primary analysis. Compared with standard
formations, the odds ratio adjusted for demographic factors
(smoking and BMI) for sodium rich drug formulations was 1.14
(95% confidence interval 1.09 to 1.18). The fully adjusted
exposure odds ratio for all covariates for sodium-rich drug
formulations for the cases was 1.16 (1.12 to 1.21) compared
with controls.
Secondary endpoint
When we examined individual components of the composite
endpoint (table 3⇓), adjusted exposure odds ratios in cases were
0.94 (0.88 to 1.00) for incident non-fatal myocardial infarction,
1.22 (1.16 to 1.29) for incident non-fatal stroke, and 0.70 (0.31
to 1.59) for vascular death. For other secondary endpoints
adjusted odds ratios were 7.18 (6.74 to 7.65) for hypertension,
0.98 (0.93 to 1.04) for incident heart failure, and 1.28 (1.23 to
1.33) for all cause mortality.
Effect of cumulative dose
Compared with controls the adjusted odds ratios were 1.10 (0.99
to 1.22) for the lowest third (≤7120 mmol sodium), 1.33 (1.20
to 1.48) for the middle third (7121-30 285 mmol sodium), and
1.31 (1.18 to 1.45) for the high third (>30 285 mmol sodium).
A test for linear trend showed there was significant trend in the
dose-response relation (P<0.01).
Further analysis
To explore these findings further, we also performed a cohort
study. The sodium cohort was defined as people who had at
least two prescriptions for sodium-containing effervescent,
dispersible or soluble formulations during the study period (table
1⇓) and the standard cohort was defined as those who had at
least two prescriptions for non-dispersible, non-effervescent,
or non-soluble versions of the drugs used by the sodium cohort
during the study period.
Compared with the standard cohort, the unadjusted and adjusted
hazard ratios for the composite endpoint in the sodium cohort
were 1.24 (95% confidence interval 1.20 to 1.29) and 1.17 (1.13
to 1.21), which supports the results of the case-control analysis.
Further analysis in which we used only those patients without
any missing data (n=68 224) showed an adjusted hazard ratio
of 1.20 (1.12 to 1.27), which was similar to the main result.
Discussion
Principal findings
Patients who experienced the composite outcome of primary
outcome of incident non-fatal myocardial infarction, incident
non-fatal stroke, or vascular death were more likely to have
been prescribed sodium-containing formulations of drugs
compared with people who had not experienced this outcome
(controls). Subsequent secondary analyses showed that the
increased risk of stroke was the component of the composite
endpoint that was driving the primary outcome (odds ratio 1.20,
95% confidence interval 1.15 to 1.26). This increased risk of
stroke was probably associated with the increased risk of
hypertension (7.18, 6.74 to 7.65). The exposure odds ratio for
all cause mortality was also significantly higher (1.29, 125 to
1.34).
The significantly increased exposure odds ratio for stroke is
consistent with the results of a recently published meta-analysis
of sodium exposure.10 Furthermore, it has been previously shown
that dietary sodium contributes significantly to resistance to
antihypertensive treatment.11 The increased exposure odds ratio
for incident stroke risk is consistent with numerous published
studies of sodium intake including a recent meta-analysis.12
Likewise, the increase in exposure odds ratio for all cause
mortality is consistent with the findings of the Third National
Health and Nutrition Examination Survey (NHANES III), in
which higher sodium intake was associated with increased all
cause mortality (hazard ratio 1.20, 95% confidence interval 1.03
to 1.41, per 1000 mg/day.13 Thus, we have shown significant
and biologically plausible serious adverse effects of
sodium-containing prescribed drugs compared with standard
drugs.
To put these findings into context, the median sodium
consumption from sodium-containing drugs alone in our study
was 106.8 mmol/day. This amount is higher than the current
recommended dietary intake of 104 mmol/day.
We did not observe an increase in the incidence of heart failure,
despite an increase in hypertension. A recent review of the
currently available evidence, however, suggests that the
association between sodium intake and incident heart failure is
not as clear cut as one might assume.14 Indeed, several studies
have found a worsening outcome with sodium restriction
because of neurohumoral activation.
Comparison with other studies
We acknowledge that there is still some controversy regarding
the relation between dietary sodium and cardiovascular events.
Some meta-analyses and systematic reviews on the effect of
dietary sodium on cardiovascular health have reached opposite
conclusions.10 15 Even large surveys such as NHANES I16 and
II17 have shown conflicting results with regards to the relation
between dietary sodium and cardiovascular events. Some
researchers have since suggested that there might either be an
inverse or a J shaped curve relation between dietary sodium and
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event rates for cardiovascular disease.18 Although we found an
increased risk of incident hypertension, incident stroke, and all
cause mortality in patients prescribed sodium-containing drugs,
we did not detect a significant increase in the risk of myocardial
infarction or vascular death. This study therefore supports the
effect of sodium-induced hypertension, through ingested drugs,
on the incidence of stroke.
It might be that taking sodium-containing formulations is
associated with less good health behaviour and that this led to
fewer contacts with health professionals. This seems unlikely,
however, as initiating a prescription for a sodium-containing
drug itself would necessitate contact with a general practitioner.
Our data were adjusted for recorded smoking, alcohol intake,
and deprivation scores, but we could not determine other aspects
of health behaviour such as adherence to treatment or poor diet.
This requires further exploration. We adjusted for other
covariates, such as oesophageal disease, as described in the
methods section.
We believe that our findings are potentially of public health
importance. The sodium content of medicines seems to be an
important topic that needs to be dealt with by regulatory
agencies. As a minimum, the public should be warned about
the potential hazards of high sodium consumption in prescribed
medicines, and these should be clearly labelled with the sodium
content in the same way as foods are labelled. Although we did
not study non-prescription or over-the-counter medicines, we
think that it is reasonable to extrapolate our findings to these
medicines. Arguably, over-the-counter preparations that have
more questionable therapeutic benefit should have their
risk-benefit balance reassessed. Pharmaceutical innovation to
reduce the sodium content of drug formulations while preserving
the desired effervescent, soluble, or dispersible characteristics
would be a wholly desirable goal.
The relation between salt intake and cardiovascular risk in
humanswas recognised 60 years agowhen Lewis Dahl proposed
that blood pressure rises linearly with salt intake.19 The strength
of this relation has been shown in large studies such as the
International Study of Salt and Blood pressure (INTERSALT
study), involving more than 10 000 patients; in populations with
a high salt intake the relation between blood pressure and age
was stronger than in populations with a low salt intake.20
Despite the overwhelming evidence of the effect of dietary
sodium on blood pressure and cardiovascular risk, there is
currently little clinical evidence on the effect of widely used
sodium-containing formulations such as effervescent,
dispersible, and soluble drugs on patient health. One small pilot
study looked at the effect of sodium-containing formulations
on blood pressure in elderly patients with hypertension and
uncontrolled blood pressure treated with effervescent
paracetamol (3 g/day) for osteoarthritis.21 Blood pressure was
measured before and after (four weeks or more) switching
paracetamol from the effervescent formulation to a standard
formulation. Switching to standard paracetamol tablets was
associated with 13.1/2.5 mm Hg reduction in blood pressure.
This study provides another biologically plausible mechanism
to support a causal association between prescribed
sodium-containing formulations and increased cardiovascular
risk.
Strengths
This was a large general practice population database study with
a mean follow-up of 7.23 years. As such it is likely to reflect
usual healthcare in the UK. We studied cardiovascular events
rather than an intermediate surrogate measure. Compared with
a time dependent survival analysis, a nested case-control analysis
has superior computational efficiency22 while producing odds
ratios that are unbiased estimators of incidence rate ratios, with
little or no loss in precision23
Limitations
There might be coding misclassification for the exposures,
outcomes, and covariates in the database. The present study is
observational and other potential confounding factors and biases
could not be fully controlled. Data on unmeasured or
unmeasurable risk factors such as health behaviour and family
history were not available. We had no data on dietary sodium
and could not control for this. Finally, we could not control for
medicines bought over-the counter. On the basis that people
who take sodium-containing formulations do so for a reason it
is likely that consumption of over-the-counter drugs would
mirror prescribed formulations and this could tend to amplify
the total sodium load.
Conclusions and policy implications
Patients experiencing incident non-fatal myocardial infarction,
incident non-fatal stroke, or vascular death (cases) had a greater
exposure to sodium-containing effervescent, dispersible, and
soluble drugs than controls. The primary outcome was largely
driven by stroke, which is consistent with the increased risk of
hypertension shown. The odds ratio for all cause mortality was
also increased with these sodium-containing drugs. Our results
suggest that physicians should prescribe sodium-containing
formulations with caution and only if there are compelling
reasons to do so. Sodium loaded effervescent, soluble, or
dispersible tablets should be avoided in patients at risk of
hypertension, and patients prescribed these drugs should be
carefully monitored for the emergence of hypertension.
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Tables
Table 1| Examples of sodium content per tablet and maximum daily ingested sodium for selected sodium-containing formulations
Maximum daily Na+ (mmol/day)Na+ per tablet (mmol)Formulation
148.818.6Paracetamol soluble tablet 500 mg
142.417.8Paracetamol with codeine phosphate effervescent tablet 500 mg + 30 mg
142.417.8Co-codamol sugar-free effervescent powder 30 mg + 500 mg
135.216.9Paracetamol with codeine phosphate effervescent tablet 500 mg + 8 mg
135.216.9Paracetamol with codeine phosphate effervescent tablet 500 mg + 30 mg (preparation 1)
113.614.2Paracetamol with codeine phosphate effervescent tablet 500 mg + 30 mg (preparation 2)
72.012.0Metoclopramide with aspirin effervescent tablet 5 mg + 325 mg
48.012.0Metoclopramide with aspirin effervescent tablet 5 mg + 450 mg
52.88.8Ibuprofen soluble tablet 200 mg
8.48.4Ascorbic acid effervescent tablet 1 g
6.56.5Aspirin effervescent tablet 300 mg
6.06.0Calcium lactate gluconate with calcium carbonate effervescent tablets 2263 mg + 1750 mg
13.84.6Zinc sulphate sugar-free effervescent tablets 125 mg
13.84.6Zinc sulphate monohydrate effervescent tablet 125 mg
36.04.5Calcium gluconate effervescent tablet 1 g
56.03.5Paracetamol soluble tablet 120 mg
4.62.3Calcium carbonate with colecalciferol effervescent tablet 1500 mg + 10 µg
1.80.9Calcium carbonate effervescent tablet 1.25 g
0.40.2Calcium carbonate and colecalciferol effervescent granules 1250 mg + 440 IU
0.40.2Calcium carbonate + colecalciferol effervescent granules 1.25 g + 11 µg
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Table 2| Baseline characteristics of patients in UK Clinical Practice Research Datalink database with individual components of primary
study composite endpoint of hypertension, incident heart failure, and all causemortality (cases) andmatched controls. Figures are numbers
(percentage) of patients unless stated otherwise
P valueControls (n=61 072)Cases (n=61 072)
—69 (12.4)69 (12.3)Mean (SD) age (years)
—25 281 (41)25 281 (41)Men
BMI:
<0.01782 (1)886 (2)<18.5
15 354 (25)15 287 (25)18.5-24.9
17 536 (29)17 618 (29)25-29.9
9904 (16)10 611 (17)≥30
—17 496 (22)16 670 (27)Missing
Smoking status:
<0.019732 (16)8120 (13)None
8597 (14)11 288 (19)Current smoker
29 068 (48)26 685 (44)Ex-smoker
—16375 (22)14 979 (25)Missing
Disease history:
<0.017373 (12)11 653 (19)Angina
<0.013373 (6)4606 (8)Heart failure
<0.011470 (2)2507 (4)Peripheral vascular disease
<0.012764 (5)3188 (5)Migraine
0.06108 (0.2)136 (0.22)Oesophageal disease
<0.016848 (11)9485 (16)Diabetes
<0.014672 (7)5234 (89)Chronic kidney disease
<0.015325 (9)6113 (10)COPD
Drug history:
<0.0135 497 (58)44 957 (74)Cardiovascular disease drugs
<0.0117 183 (28)21 666 (36)ACE/ARB
<0.0120 562(34)22 381 (37)Proton pump inhibitors
<0.012154 (4)2811 (5)Potassium
<0.0114 932 (25)16 784 (28)Antipsychotic
<0.011 (0)3 (0)HIV
<0.013924 (6)4486 (7)Steroids
<0.0142 299 (69)40 940 (67)NSAIDs
BMI=body mass index; COPD=chronic obstructive pulmonary disease; ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin receptor blockers;
NSAIDs=non-steroidal anti-inflammatories.
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Table 3| Odds ratios and 95% confidence intervals for composite cardiovascular outcome* and individual outcomes for sodium-containing
formulations group compared with standard formulations group (OR=1)
OR (95% CI)
Adjusted†Unadjusted
1.16 (1.12 to 1.21)1.13 (1.09 to 1.18)Composite cardiovascular outcome*
Individual outcomes
0.94 (0.88 to 1.00)0.90 (0.85 to 0.96)Incident non-fatal myocardial infarction
1.22 (1.16 to 1.29)1.21 (1.15 to 1.28)Incident non-fatal stroke
0.70 (0.31 to 1.59)0.62 (0.31 to 1.24)Vascular death
7.18 (6.74 to 7.65)6.80 (6.41 to 7.21)Hypertension
0.98 (0.93 to 1.04)0.95 (0.91 to 1.00)Heart failure
1.28 (1.23 to 1.33)1.30 (1.25 to 1.35)All cause mortality
*Incident non-fatal myocardial infarction, incident non-fatal stroke, and vascular death.
†See methods sections for details of adjustment.
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